Showing results (151-160 of 277) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Investigational New Drugs|November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumorsSharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
The Journal of Clinical Investigation|July 3, 2025
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphomaJithma P Abeykoon, Shuhei Asada, Guangli Zhu, et al.
Cancer Research Communications|June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Molecular Cancer Therapeutics|April 15, 2018
RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK BlockadeBruno Bockorny, Maria Rusan, Wankun Chen, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Molecular Cancer Therapeutics|February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancerAna C Garrido-Castro, Noah Graham, Lestat R Ali, et al.
Pageof 28